The estimated Net Worth of Avery W Catlin is at least $1.42 millió dollars as of 11 May 2017. Mr. Catlin owns over 5,000 units of Provention Bio stock worth over $1,174,060 and over the last 16 years he sold PRVB stock worth over $0. In addition, he makes $246,366 as Independent Director at Provention Bio.
Avery has made over 18 trades of the Provention Bio stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of PRVB stock worth $30,750 on 11 May 2017.
The largest trade he's ever made was exercising 183,333 units of Provention Bio stock on 6 December 2013 worth over $1,495,997. On average, Avery trades about 8,689 units every 60 days since 2009. As of 11 May 2017 he still owns at least 47,000 units of Provention Bio stock.
You can see the complete history of Mr. Catlin stock trades at the bottom of the page.
Avery W. Catlin CPA serves as Independent Director of the Company. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Mr. Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions. Prior to Celldex, Mr. Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Mr. Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Mr. Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him a valuable member of our board of directors.
As the Independent Director of Provention Bio, the total compensation of Avery Catlin at Provention Bio is $246,366. There are 13 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
Avery Catlin is 72, he's been the Independent Director of Provention Bio since 2018. There are no older and 17 younger executives at Provention Bio.
Avery's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski és Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: